April 27, 2012 at 16:00 PM EDT
Dynavax Reports First Quarter 2012 Financial Results

BERKELEY, CA -- (Marketwire) -- 04/27/12 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2012, including $106.9 million in cash, cash equivalents and marketable securities at March 31, 2012. This compared to $114 million at December 31, 2011. Total cash for the first quarter of 2012 included $8.6 million in milestone payments from Dynavax's collaborative partners.

Total revenues were $2.4 million for the first quarter 2012, an increase over the $1.7 million reported for the first quarter of 2011 due primarily to the recognition of collaboration revenue under the Company's partnership with AstraZeneca.

Total operating expenses of $18.2 million for the first quarter 2012 decreased from the $19.7 million reported for the first quarter of 2011, resulting primarily from the completion of certain clinical activities for HEPLISAV.

Net loss for the first quarter 2012 of $16.5 million improved from the loss of $18.5 million reported for the same period in 2011.

About HEPLISAV

HEPLISAV™ is an investigational adult hepatitis B vaccine. In earlier Phase 3 trials, HEPLISAV demonstrated increased, rapid protection with fewer doses than current licensed vaccines. Dynavax has worldwide commercial rights to HEPLISAV. HEPLISAV combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist known as 1018 ISS to enhance the immune response.

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The Company's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide rapid and earlier protection with fewer doses than currently licensed vaccines. For more information visit www.dynavax.com.

- tables to follow -

                      DYNAVAX TECHNOLOGIES CORPORATION
                   CONSOLIDATED STATEMENTS OF OPERATIONS
                  (In thousands, except per share amounts)
                                (Unaudited)

                                                        Three Months Ended
                                                             March 31,
                                                       --------------------
                                                          2012       2011
                                                       ---------  ---------
Revenues:
  Collaboration revenue                                $     929  $     366
  Grant revenue                                            1,087        889
  Service and license revenue                                334        489
                                                       ---------  ---------
Total revenues                                             2,350      1,744

Operating expenses:
  Research and development                                12,405     14,672
  General and administrative                               5,793      4,754
  Amortization of intangible assets                            -        245
                                                       ---------  ---------
Total operating expenses                                  18,198     19,671
                                                       ---------  ---------

Loss from operations                                     (15,848)   (17,927)

Interest income                                               52         33
Interest expense                                            (587)      (490)
Other expense                                               (122)       (82)
                                                       ---------  ---------

Net loss                                               $ (16,505) $ (18,466)
                                                       =========  =========

Basic and diluted net loss per share                   $   (0.11) $   (0.16)
                                                       =========  =========

Shares used to compute basic and diluted net loss per
 share                                                   155,431    115,726
                                                       =========  =========


                      DYNAVAX TECHNOLOGIES CORPORATION
                         SELECTED BALANCE SHEET DATA
                               (In thousands)
                                 (Unaudited)

                                                   March 31,    December 31,
                                                      2012          2011
                                                 ------------- -------------
Assets
  Cash and cash equivalents and marketable
   securities                                    $     106,881 $     113,961
  Property and equipment, net                            6,962         6,163
  Goodwill                                               2,498         2,312
  Other assets                                           4,335        11,666
                                                 ------------- -------------
Total assets                                     $     120,676 $     134,102
                                                 ============= =============

Liabilities and stockholders'equity
  Accounts payable                               $       2,358 $       2,040
  Accrued liabilities                                    6,932         8,776
  Current portion of deferred revenue                    3,801         4,210
  Non-current portion of deferred revenue                5,849         6,386
  Short-term note payable to Holdings                   13,357        12,810
  Stockholders' equity                                  88,379        99,880
                                                 ------------- -------------
Total liabilities and stockholders' equity       $     120,676 $     134,102
                                                 ============= =============

Contacts:
Jennifer Lew
Vice President, Finance
510-665-7217
Email Contact

Michael Ostrach
Vice President and Chief Business Officer
510-665-7257
Email Contact

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here